Patents Assigned to Genentech
  • COMBINATION THERAPY FOR CANCER COMPRISING PD-1 AXIS BINDING ANTAGONIST AND IL6 ANTAGONIST
    Publication number: 20210332143
    Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.
    Type: Application
    Filed: March 4, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Mahrukh Huseni, Joanna E. Klementowicz, Yijin Li, Li-Fen Liu, Sanjeev Mariathasan, Mark Merchant, Luciana Molinero, Lifen Wang, Nathaniel West, Patrick Williams, Chi Yung Yuen, Edward Namserk Cha, Yulei Wang
  • ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20210332064
    Abstract: 3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
  • ANTI-TAU ANTIBODIES AND METHODS OF USE
    Publication number: 20210332114
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: December 3, 2020
    Publication date: October 28, 2021
    Applicants: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Cystine knot scaffold platform
    Patent number: 11155586
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • Bioreactors with multiple or adjustable-position agitator designs
    Patent number: 11155777
    Abstract: Described herein are bioreactor support structures configured to be used with containers having different designs, and methods for making and using such bioreactors. The support structures described herein may include two or more agitator motors and control systems or an adjustable-position agitator motor, a removable spacer and/or lid, multiple configurations for ports and probes, and multiple exhaust filter heating blankets. Also described herein are methods of manufacturing a multi-agitator motor or adjustable-position agitator motor bioreactor, as well as methods of modifying an existing support structure to be used with a container not originally designed to be used with the existing support structure, and methods for operating these bioreactors.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Ekta Mahajan, Kelsey Dent, Edward Chan, Terry Hudson, Neria Daniel
  • Pyrazolopyrimidine compounds and methods of use thereof
    Patent number: 11155557
    Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: F. Anthony Romero, Mark Zak, Guiling Zhao, Paul Gibbons, Wei Li, Yun-Xing Cheng, Po-Wai Yuen, Limin Cheng
  • Methods of treating acute pancreatitis using IL-22 fc fusion proteins
    Patent number: 11155591
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
    Patent number: 11154616
    Abstract: The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventor: Daniel ShinYu Chen
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20210324098
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA
  • METHODS OF TREATING CANCER WITH PI3K ALPHA INHIBITORS AND METFORMIN
    Publication number: 20210322426
    Abstract: Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K alpha inhibitor.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Susan Greene, Stephanie Joo, Jennifer Schutzman
  • Therapeutic compounds and methods of use thereof
    Patent number: 11149002
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • HUMANIZED ANTIBODY
    Publication number: 20210317197
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: November 16, 2020
    Publication date: October 14, 2021
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS
    Publication number: 20210317501
    Abstract: Provided herein are cell lines (e.g., HEK293 cell lines) that comprise a loss-of-function mutation in each of the human Bax and Bak genes, as well as cell cultures comprising the cell lines. The cell lines and/or cell cultures may find use, e.g., in methods for producing a recombinant polypeptide (such as an antibody or antigen-binding fragment thereof) or a viral vector.
    Type: Application
    Filed: June 8, 2021
    Publication date: October 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Tia Alexandra ARENA, Athena W. WONG
  • MODIFIED MAMMALIAN CELLS
    Publication number: 20210309989
    Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
    Type: Application
    Filed: March 26, 2021
    Publication date: October 7, 2021
    Applicant: GENENTECH, INC.
    Inventors: Michael Wilson LAIRD, Shahram MISAGHI, Amy SHEN, Anthony TOMLINSON, Inn Huam YUK
  • Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
    Patent number: 11136365
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen
  • Synthesis of labeled imidazo[1,2-A]pyrimidines
    Patent number: 11136330
    Abstract: A method of synthesizing comprising a step of making an imidazo-pyrimidine compound by coupling a first compound of formula (II) with a second compound of formula (III) Followed by a deprotection and tosylation step. The methods are able to produce an isotopically substituted molecule having upwards of 95% purity relative to non-isotopically substituted molecules.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: October 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Kyle Bradley Pascual Clagg, Nicholas Andrew White, Haiming Zhang, Francis Gosselin, William Nack, Paul D. O'Shea
  • ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
    Publication number: 20210301005
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Application
    Filed: March 18, 2021
    Publication date: September 30, 2021
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching LIANG, Joseph R. ARRON, Daryle DEPIANTO, Wendy Green HALPERN, WeiYu LIN, Patrick J. LUPARDUS, Thirumalai Rajan RAMALINGAM, Dhaya SESHASAYEE, Tianhe SUN, Tulika TYAGI, Jia WU, Yan WU, Jian Ping YIN
  • AZAINDOLES AS INHIBITORS OF HPK1
    Publication number: 20210299110
    Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 30, 2021
    Applicant: Genentech, Inc.
    Inventors: Timothy HEFFRON, Sushant MALHOTRA, BinQing WEI, Bryan CHAN, Lewis GAZZARD, Emanuela GANCIA, Michael LAINCHBURY, Andrew MADIN, Eileen SEWARD, Yonghan HU
  • ANTI-KLK5 ANTIBODIES AND METHODS OF USE
    Publication number: 20210301032
    Abstract: The invention provides anti-KLK5 antibodies and methods of using the same.
    Type: Application
    Filed: November 17, 2020
    Publication date: September 30, 2021
    Applicant: Genentech, Inc.
    Inventors: Cecilia P.C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
  • VALIDATING INTERPRETABILITY OF QSAR AND QSPR MODELS
    Publication number: 20210304853
    Abstract: A method performed on a computer or computing system, the method comprising steps for aiding interpretability of calculated values in the context of molecular structural features. The method starts with a machine learning model of a pharmacokinetic or physicochemical property of a molecule, derived from a training set of molecules, and provides a user with an interpretability model of the machine learning model for a set of molecules of interest.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 30, 2021
    Applicant: Genentech, Inc.
    Inventors: Kim BRANSON, Cuong Quoc NGUYEN